NCT05936359 A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms Status RECRUITING Phase PHASE1
NCT05909943 Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum Disorders Status WITHDRAWN Phase PHASE1/PHASE2
NCT05870475 Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV Status RECRUITING Phase PHASE2
NCT05762640 Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH) Status RECRUITING Phase PHASE2
NCT05745714 HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies Status RECRUITING Phase PHASE1/PHASE2
NCT05722912 Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD Status APPROVED_FOR_MARKETING Phase N/A
NCT05714072 A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis Status RECRUITING Phase PHASE1
NCT05663827 Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease Status COMPLETED Phase PHASE3
NCT05622318 De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05600855 Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model Status COMPLETED Phase PHASE2
NCT05599256 Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model Status RECRUITING Phase PHASE2
NCT05592015 Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia Status RECRUITING Phase PHASE2
NCT05579769 Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies. Status TERMINATED Phase PHASE2
NCT05566535 Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical Practice Status UNKNOWN Phase N/A
NCT05491304 Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis Status RECRUITING Phase PHASE4
NCT05447260 A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis Status UNKNOWN Phase PHASE4
NCT05440942 Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma Status COMPLETED Phase PHASE1
NCT05413356 Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome Status UNKNOWN Phase PHASE2
NCT05410470 Efficacy and Safety of Ruxolitinib in Patients With Myelofibrosis Status COMPLETED Phase N/A